BCL2L1 and non-Hodgkin lymphoma: In addition, treating the HER2-negative DoHH-2 NHL cells with [Bi-213]anti-HER2 (Figure 7C) or the radio-/chemoresistant DoHH-2betaR and DoHH-2gammaR cells with [Bi-213]anti-HER2 (Figure 7C) or the CD20-negative HL-60 cells with [Bi-213]anti-CD20 (Figure 7D) did not lead to significant changes in the protein levels of Bcl-xL or XIAP.